Corpus Intelligence EBITDA Bridge — SARAH D CULBERTSON 2026-04-27 01:25 UTC
EBITDA Bridge — SARAH D CULBERTSON
CCN 141333 | IL | 22 beds | Current EBITDA $-868K → Pro Forma $498K (+$1.4M)
🛡️ Public data only — no PHI permitted on this instance.
EBITDA BRIDGE  ·  CCN 141333

SARAH D CULBERTSON
value-creation walk.

7-lever RCM bridge from current EBITDA to pro-forma — denial / underpay / DAR / coding / contract / cost discipline / cash acceleration. Each lever shows current vs benchmark target with data provenance.

$26.0M
Net Revenue HCRIS
$-868K
Current EBITDA COMPUTED
+$1.4M
RCM EBITDA Uplift
$498K
Pro Forma EBITDA
+526bps
Margin Improvement
$996K
WC Released (1x)

Bridge Realization Estimate

ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)

59%
Realization (C)
$1.4M
Modeled Uplift
$803K
Risk-Adjusted
-$564K
Execution Discount
Occupancy RateLower Occupancy Rate reduces execution likelihood
Bed CountHigher Bed Count increases execution likelihood
Commercial Payer %Higher Commercial Payer % increases execution like
Revenue per BedRevenue per Bed has minimal effect on execution
Net-to-Gross RatioNet-to-Gross Ratio has minimal effect on execution

Expected realization: 59% of modeled bridge. Strengths: Bed Count, Commercial Payer %. Risks: Occupancy Rate. Risk-adjusted uplift: $0.8M (vs $1.4M modeled).

EBITDA Bridge — 7 RCM Levers

Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).

Cost to Collect
Cost Savings | 12mo ramp
$520K
+200bp
Denial Rate Reduction
Revenue | 12mo ramp
$514K
+198bp
A/R Days Reduction
Cash Accel | 9mo ramp
$316K
+122bp
Clean Claim Rate
Cost Savings | 6mo ramp
$17K
+6bp
Total EBITDA Impact$1.4M

Lever Detail

Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.

LeverCurrentTargetRevenueCostEBITDAWCRamp
Cost to Collect4.5% DEFAULT2.5% BENCHMARK$0$520K$520K$012mo
Denial Rate Reduction12.0% DEFAULT6.5% BENCHMARK$500K$14K$514K$012mo
A/R Days Reduction52.00 DEFAULT38.00 BENCHMARK$80K$236K$316K$996K9mo
Clean Claim Rate88.0% DEFAULT96.0% BENCHMARK$0$17K$17K$06mo
Net Collection Rate93.5% DEFAULT49.2% BENCHMARK$0$0$0$018mo
CDI / Case Mix Index135.0% DEFAULT142.0% BENCHMARK$0$0$0$018mo

Implementation Timing Curve

Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.

LeverM0M3M6M9M12M18M24M36
Cost to Collect$0$130K$260K$390K$520K$520K$520K$520K
Denial Rate Reduction$0$129K$257K$386K$514K$514K$514K$514K
A/R Days Reduction$0$105K$211K$316K$316K$316K$316K$316K
Clean Claim Rate$0$8K$17K$17K$17K$17K$17K$17K
Cumulative$0$372K$744K$1.1M$1.4M$1.4M$1.4M$1.4M

Returns Sensitivity (IRR / MOIC)

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $1.4M is added at exit.

Entry \ Exit9.0x10.0x11.0x11.5x12.0x
8.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x
9.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x
10.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x
11.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x
12.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x

Covenant Headroom (at 10x Entry, 6.5x Max Leverage)

99.0x
Entry Leverage
-14.7x
Pro Forma Leverage
21.2x
Headroom (turns)
327%
EBITDA Cushion

Pro forma EBITDA can decline 327% before the 6.5x covenant trips. RCM uplift reduces leverage from 99.0x to -14.7x, adding 113.7 turns of cushion.

5-Year Value Creation Waterfall

EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).

Base EBITDARCM UpliftTotalMargin
Entry$-868K$-868K-3.3%
Year 1$-894K+$911K$17K0.1%
Year 2$-921K+$1.4M$445K1.7%
Year 3$-949K+$1.4M$418K1.6%
Year 4$-977K+$1.4M$389K1.5%
Year 5$-1.0M+$1.4M$360K1.4%
$-8.7M
Entry EV (10x)
$4.0M
Exit EV (11x)
$12.6M
Value Created
$360K
Exit EBITDA
$-1.4M
Organic Growth
$13.7M
RCM Value Creation
$360K
Multiple Expansion

Achievement Sensitivity

What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.

Lever50%75%100%120%
Cost to Collect$260K$390K$520K$623K
Denial Rate Reductio$257K$386K$514K$617K
A/R Days Reduction$158K$237K$316K$379K
Clean Claim Rate$8K$12K$17K$20K
Total$683K$1.0M$1.4M$1.6M

Peer Context — Where This Hospital Sits

Key metrics vs 68 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.

MetricHospitalP25P50P75Percentile
Op Margin-3.3%-6.7%-1.2%7.3%
P42
Net-to-Gross46.9%35.1%43.7%49.2%
P64
Occupancy5.8%17.4%26.1%42.3%
P1
Rev/Bed$1.2M$1.1M$1.5M$2.2M
P27
Exp/Bed$1.2M$1.2M$1.5M$2.0M
P26

Bridge Methodology

Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.

Data: HCRIS FY2022 | 6,123 hospitalsSources: HCRISML